Navigation Links
The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
Date:3/5/2009

SAN ANTONIO, March 5 /PRNewswire/ -- A plentiful, inexpensive, topical compound is as effective at treating the skin lesions of Middle Eastern and African leishmaniasis as is the standard therapy, a less-available, costlier compound injected into lesions. That's one of the findings of a research team from Johns Hopkins University, Harvard University, Thomas Jefferson University and led by Reza F. Ghohestani, M.D., Ph.D., director of the Texas Institute of Dermatology and an associate professor of medicine at The University of Texas Health Science Center at San Antonio.

The panel, reporting in the prestigious peer-reviewed journal Public Library of Science Neglected Tropical Diseases, analyzed 14 major clinical research trials that enrolled 1,221 patients. The trials compared the standard therapeutics, known as pentavalent antimony compounds, with the topical treatment, paramomycin. Old World leishmaniasis infection is caused by parasites carried by the desert sandfly and can be found mainly in the Middle East, Mediterranean Sea coastal areas, Africa, and Asia.

More than 12 million people in 88 countries suffer from leishmaniasis and 2 million new cases are diagnosed annually, the authors wrote.

"Millions of people worldwide suffer with leishmaniasis, but we in South Texas should keep in mind that cutaneous leishmaniasis is not a rare entity here, either," Dr. Ghohestani said. "In our area the infection is mainly seen in people coming from Mexico and soldiers returning from Iraq."

Pentavalent antimony compounds were considered the main therapeutic option for all types of cutaneous leishmaniasis for decades. They were given intravenously, into muscle or into lesions.

"Our findings suggest that the topical paramomycin can be a good alternative for the Old World type of leishmaniasis, especially if MBCL is added," Dr. Ghohestani said. "Our group is now focused on improving delivery of paramomycin to the skin." The team is working with the Eastern Mediterranean regional office of the World Health Organization on this project.

The Texas Institute of Dermatology is the sole dermatology program in South Texas that combines basic and clinic research with clinical care. The Institute offers excellence in clinical dermatology as well as in basic and clinical research. General dermatology services are available for Skin Disorders. For more information, visit www.txdi.org or call 1-888-884-5557 Ext 2.

CONTACT: Maria E. Guerra of Texas Institute of Dermatology, 1-888-884-5557, Ext. 2, TexasDermatologyInstitute@gmail.com


'/>"/>
SOURCE Texas Institute of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Austin, Texas, Physicians Second in Nation to Perform New Procedure for Difficult-to-Treat Atrial Fibrillation Cases
2. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in Nation to Use NaviStar(R) RMT ThermoCool(R) Catheter Since Technology Received FDA Approval
3. Motor behavioral research at UH moves to prestigious Texas Medical Center
4. New Texas Study Reveals Serious Flaws in Abstinence Programs
5. Texas Association of Health Underwriters Announces 15th Annual Day at the Capitol
6. Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession
7. University of Texas engineers receive $3.2 million in National Science Foundation CAREER awards
8. Accordent Delivers Medical Lecture Capture Platform for University of Texas Health Sciences Center
9. Texas Mutual Wins National Employee Wellness Award
10. New Research Study in Houston, Texas Seeks Improved Quality of Life for People in the Future with Schizophrenia
11. Texas Health Dallas New Intensivist Program Puts Critical-Care Specialists in the ICU - All the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: